MedTrace Logo

Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

NCT00683267 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2009-05-04

No results posted yet for this study

Summary

Evaluate the efficacy, safety and tolerability of a single intraoperative dose of 4975 in patients undergoing total hip replacement

Conditions

  • Arthroplasty

Interventions

DRUG

4975, highly purified capsaicin

One dose administered by direct instillation into the surgical site

DRUG

Placebo

One dose administered by direct instillation into the surgical site

Sponsors & Collaborators

  • Anesiva, Inc.

    lead INDUSTRY

Principal Investigators

  • Shaun Comfort, MD, MBA · Anesiva, Inc.

  • William Houghton, MD · Anesiva, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-11-30
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683267 on ClinicalTrials.gov